Alzheimer’s drug cut loose from Peninsula biotech’s collaboration but another survives


The company said in May that it and its Big Pharma partner were reviewing one of its two Alzheimer's Disease-focused programs.

Previous Dayton financial veterans form new wealth management firm
Next Net Health expands predictive analytics resources